Jeff Jones
Stock Analyst at Oppenheimer
(2.42)
# 2,259
Out of 4,670 analysts
77
Total ratings
22.86%
Success rate
0.28%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CATX Perspective Therapeutics | Maintains: Outperform | $22 → $16 | $3.47 | +361.10% | 7 | Nov 22, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Outperform | $14 → $12 | $1.58 | +659.49% | 4 | Nov 19, 2024 | |
| EVH Evolent Health | Maintains: Outperform | $34 → $28 | $11.25 | +148.89% | 3 | Nov 18, 2024 | |
| YMAB Y-mAbs Therapeutics | Initiates: Outperform | $23 | $10.41 | +120.94% | 1 | Nov 18, 2024 | |
| CMMB Chemomab Therapeutics | Reiterates: Outperform | $13 → $11 | $1.65 | +566.67% | 7 | Nov 15, 2024 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Outperform | $8 → $14 | $8.95 | +56.42% | 3 | Nov 13, 2024 | |
| VTYX Ventyx Biosciences | Reiterates: Outperform | $10 → $9 | $1.85 | +386.49% | 10 | Nov 8, 2024 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $52 → $56 | $44.98 | +24.50% | 4 | Sep 27, 2024 | |
| AVBP ArriVent BioPharma | Reiterates: Outperform | $35 → $39 | $27.45 | +42.08% | 2 | Sep 10, 2024 | |
| IMCR Immunocore Holdings | Reiterates: Outperform | $87 → $89 | $32.28 | +175.71% | 1 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $12.98 | +246.69% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $88 | $17.47 | +403.72% | 8 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.77 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $21 | $2.73 | +669.23% | 2 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.34 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $0.36 | +33,607.87% | 3 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.61 | +831.68% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $75 | $2.73 | +2,647.25% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $110 | $1.49 | +7,282.55% | 2 | Nov 17, 2022 |
Perspective Therapeutics
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $3.47
Upside: +361.10%
Cellectar Biosciences
Nov 19, 2024
Maintains: Outperform
Price Target: $14 → $12
Current: $1.58
Upside: +659.49%
Evolent Health
Nov 18, 2024
Maintains: Outperform
Price Target: $34 → $28
Current: $11.25
Upside: +148.89%
Y-mAbs Therapeutics
Nov 18, 2024
Initiates: Outperform
Price Target: $23
Current: $10.41
Upside: +120.94%
Chemomab Therapeutics
Nov 15, 2024
Reiterates: Outperform
Price Target: $13 → $11
Current: $1.65
Upside: +566.67%
Corvus Pharmaceuticals
Nov 13, 2024
Reiterates: Outperform
Price Target: $8 → $14
Current: $8.95
Upside: +56.42%
Ventyx Biosciences
Nov 8, 2024
Reiterates: Outperform
Price Target: $10 → $9
Current: $1.85
Upside: +386.49%
Kymera Therapeutics
Sep 27, 2024
Maintains: Outperform
Price Target: $52 → $56
Current: $44.98
Upside: +24.50%
ArriVent BioPharma
Sep 10, 2024
Reiterates: Outperform
Price Target: $35 → $39
Current: $27.45
Upside: +42.08%
Immunocore Holdings
Aug 9, 2024
Reiterates: Outperform
Price Target: $87 → $89
Current: $32.28
Upside: +175.71%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $12.98
Upside: +246.69%
Aug 7, 2024
Maintains: Outperform
Price Target: $80 → $88
Current: $17.47
Upside: +403.72%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $0.77
Upside: -
May 10, 2024
Maintains: Outperform
Price Target: $16 → $21
Current: $2.73
Upside: +669.23%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.34
Upside: -
May 25, 2023
Maintains: Outperform
Price Target: $120
Current: $0.36
Upside: +33,607.87%
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.61
Upside: +831.68%
Mar 24, 2023
Reiterates: Outperform
Price Target: $75
Current: $2.73
Upside: +2,647.25%
Nov 17, 2022
Maintains: Outperform
Price Target: $160 → $110
Current: $1.49
Upside: +7,282.55%